Strategies And Future Plans

  • Leverage on Company as the dominant market leader and an established brand in Singapore and Hong Kong

    • Develop position further in existing markets
    • Increase capacity through new proposed headquarters and facility at Yishun A'Posh Bizhub
  • Leverage on expanded clinical use to drive perceived utility of cord blood banking

  • Diversify into secondary and complementary services

    • Entered into, inter alia, co-operation agreement with Cordlife Stem Cell Technology Limited, giving the Group the rights to use certain technology and expertise with respect to umbilical cord tissue banking, thus allowing for the offering of umbilical cord tissue banking services
  • Growth through accretive acquisitions in selected markets

    • Broaden service offering and expand geographical coverage in Asia through accretive acquisitions
    • Granted right of first refusal ("ROFR") to acquire relevant businesses in Indonesia, the Philippines and India
    • Entered into a subscription agreement with CS Cell Technologies Pte. Ltd. ("CSCT"), a wholly-owned subsidiary of CBB, to invest S$1.5 million in CSCT, which holds 85% of Cordlife Sciences India Pvt. Ltd. ("Cordlife India") for expansion of operations of CSCT and Cordlife India only